Liver function may change how anxiety drug works
NCT ID NCT07457190
First seen Apr 09, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This early-stage study looks at how the drug buagafuran (AF-5) behaves in people with liver impairment compared to those with normal liver function. Twenty-four adults will receive a single 30 mg dose, and researchers will measure drug levels in the blood and monitor safety. The goal is to understand if liver problems affect how the drug is processed, which could guide future dosing for anxiety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Union Pharmaceutical Factory Ltd
Beijing, Beijing Municipality, 102600, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Buagafuran (AF-5)
What this could lead to
If successful, this study could help determine safe dosing of buagafuran for people with liver problems who have anxiety.
What could go wrong
This is a very early, small Phase 1 study focused on safety and drug levels, not on treating anxiety. It may not lead to any treatment benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.